The session on drug shortages will cover legislation, stakeholder responsibilities, and the Belgian situation: number, duration, and causes of shortages, as well as critical medicines. It explains the role of the FAMHP, its actions, and the importance of timely notifications. Topics also include the definition and types of unavailability, Farmastatus and competition concerns, EU legislation, the Critical Medicines Act, and derogations.